Litemed India, a Hyderabad-based health-tech company, has launched Curapod M, a science-led, drug-free solution designed to manage menstrual pain and cramps. 

Fully engineered and manufactured in India, the device combines medical-grade photobiomodulation (PBM), adaptive personalisation and digital intelligence.

Curapod M is licensed by the Central Drugs Standard Control Organisation (CDSCO) and registered with the US Food and Drug Administration (US FDA). 

The device is designed to be used around the lower abdomen, employing red and near-infrared wavelengths through PBM to target biological processes associated with menstrual pain, including prostaglandin-linked pathways involved in cramping.

According to the company, clinical evaluation found that 80% of women experienced zero pain after using Curapod M. The hormone-free and drug-free therapy is supported by a proprietary adaptive engine that personalises treatment based on the user’s cycle, pain patterns and therapy history.

“Menstrual pain is driven by real biological processes. With Curapod M, the intent was to go beyond simply responding to the sensation of pain and build technology that works further upstream on the mechanisms associated with it. That is where photobiomodulation and adaptive personalisation come together,” said Surya Prakash, Founder and Chief Technology Officer, Curapod.

“For generations, women have learned to organise parts of their lives around menstrual pain. We believe the next generation should inherit something different. Curapod M is our attempt to change that expectation through science and technology,” said Sri Velliyur, Co-Founder and CEO, Curapod.

Curapod M is expected to roll out across India through Curapod’s website, Amazon and Flipkart at an indicative launch price of around Rs. 11,999. 

The company plans to make the product available across metropolitan and Tier 2 markets.

The launch comes against the backdrop of the significant prevalence and wider impact of menstrual pain in India. A 2025 meta-analysis of 31 studies estimated that 53% of adolescent girls aged 10–19 experience menstrual pain, while studies have linked the condition to absenteeism, reduced concentration and lower work satisfaction.

“Curapod M gives us an opportunity to build not only an India-made technology, but an India-led women’s health category with global relevance,” said Aditi Wadhwa, Chief Marketing Officer, Curapod.